2
|
Brennan JM, Al-Hejily W, Dai D, Shaw RE, Trilesskaya M, Rao SV, Brilakis ES, Anstrom KJ, Messenger JC, Peterson ED, Douglas PS, Sketch MH. Three-Year Outcomes Associated With Embolic Protection in Saphenous Vein Graft Intervention. Circ Cardiovasc Interv 2015; 8:e001403. [DOI: 10.1161/circinterventions.114.001403] [Citation(s) in RCA: 42] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Background—
Information is limited on contemporary use and outcomes of embolic protection devices (EPDs) in saphenous vein graft interventions.
Methods and Results—
We formed a longitudinal cohort (2005–2009; n=49 325) by linking National Cardiovascular Data Registry CathPCI Registry to Medicare claims to examine the association between EPD use and both procedural and long-term outcomes among seniors (65+ years), adjusting for clinical factors using propensity and instrumental variable methodologies. Prespecified high-risk subgroups included acute coronary syndrome and de novo or graft body lesions. EPDs were used in 21.2% of saphenous vein grafts (median age, 75; 23% women) and were more common in acute coronary syndrome (versus non–acute coronary syndrome; 22% versus 19%), de novo (versus restenotic; 22% versus 14%), and graft body lesions (versus aortic and distal anastomosis; 24% versus 20% versus 8%, respectively). EPDs were associated with a slightly higher incidence of procedural complications, including no reflow (3.9% versus 2.8%;
P
<0.001), vessel dissection (1.3% versus 1.1%;
P
=0.05), perforation (0.7% versus 0.4%;
P
=0.001), and periprocedural myocardial infarction (2.8% versus 1.8%;
P
<0.001). By 3 years, death, myocardial infarction, and repeat revascularization occurred in 25%, 15%, and 30% of cases, respectively. EPD use was associated with a similar adjusted risk of death (propensity score–matched hazard ratio, 0.96; 95% confidence interval, 0.91–1.02), myocardial infarction (propensity score–matched hazard ratio, 1.00; 95% confidence interval, 0.93–1.09), and repeat revascularization (propensity score–matched hazard ratio, 1.02; 95% confidence interval, 0.96–1.08) in the overall cohort and high-risk subgroups.
Conclusions—
In this contemporary cohort, EPDs were used more commonly among patients with high-risk clinical indications, yet there was no evidence of improved acute- or long-term outcomes. Further prospective studies are needed to support routine EPD use.
Collapse
Affiliation(s)
- J. Matthew Brennan
- From the Duke Clinical Research Institute, Durham, NC (J.M.B., W.A.-H., D.D., S.V.R., K.J.A., E.D.P., P.S.D., M.H.S.); Sutter Pacific Heart Centers, San Francisco, CA (R.E.S.); Carolina Pacific Medical Center, San Francisco, CA (M.T.); Veterans Affairs North Texas Healthcare System and University of Texas Southwestern Medical Center, Dallas (E.S.B.); and Denver Veterans Affairs Medical Center, CO (J.C.M.)
| | - Wesam Al-Hejily
- From the Duke Clinical Research Institute, Durham, NC (J.M.B., W.A.-H., D.D., S.V.R., K.J.A., E.D.P., P.S.D., M.H.S.); Sutter Pacific Heart Centers, San Francisco, CA (R.E.S.); Carolina Pacific Medical Center, San Francisco, CA (M.T.); Veterans Affairs North Texas Healthcare System and University of Texas Southwestern Medical Center, Dallas (E.S.B.); and Denver Veterans Affairs Medical Center, CO (J.C.M.)
| | - David Dai
- From the Duke Clinical Research Institute, Durham, NC (J.M.B., W.A.-H., D.D., S.V.R., K.J.A., E.D.P., P.S.D., M.H.S.); Sutter Pacific Heart Centers, San Francisco, CA (R.E.S.); Carolina Pacific Medical Center, San Francisco, CA (M.T.); Veterans Affairs North Texas Healthcare System and University of Texas Southwestern Medical Center, Dallas (E.S.B.); and Denver Veterans Affairs Medical Center, CO (J.C.M.)
| | - Richard E. Shaw
- From the Duke Clinical Research Institute, Durham, NC (J.M.B., W.A.-H., D.D., S.V.R., K.J.A., E.D.P., P.S.D., M.H.S.); Sutter Pacific Heart Centers, San Francisco, CA (R.E.S.); Carolina Pacific Medical Center, San Francisco, CA (M.T.); Veterans Affairs North Texas Healthcare System and University of Texas Southwestern Medical Center, Dallas (E.S.B.); and Denver Veterans Affairs Medical Center, CO (J.C.M.)
| | - Marina Trilesskaya
- From the Duke Clinical Research Institute, Durham, NC (J.M.B., W.A.-H., D.D., S.V.R., K.J.A., E.D.P., P.S.D., M.H.S.); Sutter Pacific Heart Centers, San Francisco, CA (R.E.S.); Carolina Pacific Medical Center, San Francisco, CA (M.T.); Veterans Affairs North Texas Healthcare System and University of Texas Southwestern Medical Center, Dallas (E.S.B.); and Denver Veterans Affairs Medical Center, CO (J.C.M.)
| | - Sunil V. Rao
- From the Duke Clinical Research Institute, Durham, NC (J.M.B., W.A.-H., D.D., S.V.R., K.J.A., E.D.P., P.S.D., M.H.S.); Sutter Pacific Heart Centers, San Francisco, CA (R.E.S.); Carolina Pacific Medical Center, San Francisco, CA (M.T.); Veterans Affairs North Texas Healthcare System and University of Texas Southwestern Medical Center, Dallas (E.S.B.); and Denver Veterans Affairs Medical Center, CO (J.C.M.)
| | - Emmanouil S. Brilakis
- From the Duke Clinical Research Institute, Durham, NC (J.M.B., W.A.-H., D.D., S.V.R., K.J.A., E.D.P., P.S.D., M.H.S.); Sutter Pacific Heart Centers, San Francisco, CA (R.E.S.); Carolina Pacific Medical Center, San Francisco, CA (M.T.); Veterans Affairs North Texas Healthcare System and University of Texas Southwestern Medical Center, Dallas (E.S.B.); and Denver Veterans Affairs Medical Center, CO (J.C.M.)
| | - Kevin J. Anstrom
- From the Duke Clinical Research Institute, Durham, NC (J.M.B., W.A.-H., D.D., S.V.R., K.J.A., E.D.P., P.S.D., M.H.S.); Sutter Pacific Heart Centers, San Francisco, CA (R.E.S.); Carolina Pacific Medical Center, San Francisco, CA (M.T.); Veterans Affairs North Texas Healthcare System and University of Texas Southwestern Medical Center, Dallas (E.S.B.); and Denver Veterans Affairs Medical Center, CO (J.C.M.)
| | - John C. Messenger
- From the Duke Clinical Research Institute, Durham, NC (J.M.B., W.A.-H., D.D., S.V.R., K.J.A., E.D.P., P.S.D., M.H.S.); Sutter Pacific Heart Centers, San Francisco, CA (R.E.S.); Carolina Pacific Medical Center, San Francisco, CA (M.T.); Veterans Affairs North Texas Healthcare System and University of Texas Southwestern Medical Center, Dallas (E.S.B.); and Denver Veterans Affairs Medical Center, CO (J.C.M.)
| | - Eric D. Peterson
- From the Duke Clinical Research Institute, Durham, NC (J.M.B., W.A.-H., D.D., S.V.R., K.J.A., E.D.P., P.S.D., M.H.S.); Sutter Pacific Heart Centers, San Francisco, CA (R.E.S.); Carolina Pacific Medical Center, San Francisco, CA (M.T.); Veterans Affairs North Texas Healthcare System and University of Texas Southwestern Medical Center, Dallas (E.S.B.); and Denver Veterans Affairs Medical Center, CO (J.C.M.)
| | - Pamela S. Douglas
- From the Duke Clinical Research Institute, Durham, NC (J.M.B., W.A.-H., D.D., S.V.R., K.J.A., E.D.P., P.S.D., M.H.S.); Sutter Pacific Heart Centers, San Francisco, CA (R.E.S.); Carolina Pacific Medical Center, San Francisco, CA (M.T.); Veterans Affairs North Texas Healthcare System and University of Texas Southwestern Medical Center, Dallas (E.S.B.); and Denver Veterans Affairs Medical Center, CO (J.C.M.)
| | - Michael H. Sketch
- From the Duke Clinical Research Institute, Durham, NC (J.M.B., W.A.-H., D.D., S.V.R., K.J.A., E.D.P., P.S.D., M.H.S.); Sutter Pacific Heart Centers, San Francisco, CA (R.E.S.); Carolina Pacific Medical Center, San Francisco, CA (M.T.); Veterans Affairs North Texas Healthcare System and University of Texas Southwestern Medical Center, Dallas (E.S.B.); and Denver Veterans Affairs Medical Center, CO (J.C.M.)
| |
Collapse
|